Abstract
(2) Subgroup Safety Analyses in Solid Organ Transplant (SOT) Recipients in a Phase 3 Trial of Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Cytomegalovirus (CMV) Infection (Refractory with or without Resistance; R/R)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
